These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 31292266)

  • 1. A variant erythroferrone disrupts iron homeostasis in
    Bondu S; Alary AS; Lefèvre C; Houy A; Jung G; Lefebvre T; Rombaut D; Boussaid I; Bousta A; Guillonneau F; Perrier P; Alsafadi S; Wassef M; Margueron R; Rousseau A; Droin N; Cagnard N; Kaltenbach S; Winter S; Kubasch AS; Bouscary D; Santini V; Toma A; Hunault M; Stamatoullas A; Gyan E; Cluzeau T; Platzbecker U; Adès L; Puy H; Stern MH; Karim Z; Mayeux P; Nemeth E; Park S; Ganz T; Kautz L; Kosmider O; Fontenay M
    Sci Transl Med; 2019 Jul; 11(500):. PubMed ID: 31292266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High erythroferrone expression in CD71
    Riabov V; Mossner M; Stöhr A; Jann JC; Streuer A; Schmitt N; Knaflic A; Nowak V; Weimer N; Obländer J; Palme I; Schumann C; Baldus CD; Schulze TJ; Wuchter P; Röhl H; Jawhar A; Weiss C; Boch T; Metzgeroth G; Neumann M; Hofmann WK; Nolte F; Nowak D
    Br J Haematol; 2021 Mar; 192(5):879-891. PubMed ID: 33486765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EPO-R+ myelodysplastic cells with ring sideroblasts produce high erythroferrone levels to reduce hepcidin expression in hepatic cells.
    Miura S; Kobune M; Horiguchi H; Kikuchi S; Iyama S; Murase K; Goto A; Ikeda H; Takada K; Miyanishi K; Kato J
    Blood Cells Mol Dis; 2019 Sep; 78():1-8. PubMed ID: 31082798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1.
    Ambaglio I; Malcovati L; Papaemmanuil E; Laarakkers CM; Della Porta MG; Gallì A; Da Vià MC; Bono E; Ubezio M; Travaglino E; Albertini R; Campbell PJ; Swinkels DW; Cazzola M
    Haematologica; 2013 Mar; 98(3):420-3. PubMed ID: 23300182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
    Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J
    Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
    Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythroferrone structure, function, and physiology: Iron homeostasis and beyond.
    Srole DN; Ganz T
    J Cell Physiol; 2021 Jul; 236(7):4888-4901. PubMed ID: 33372284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
    Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
    Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellström-Lindberg E
    Blood; 2017 Aug; 130(7):881-890. PubMed ID: 28634182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietic regulators of iron metabolism.
    Ganz T
    Free Radic Biol Med; 2019 Mar; 133():69-74. PubMed ID: 29981834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts.
    Ma L; Luo Y; Jiang L; Shen D; Li J; Xu W; Mei C; Zhou X; Ren Y; Ye L; Lu C; Jie J; Tong H
    Leuk Lymphoma; 2019 May; 60(5):1179-1186. PubMed ID: 30409066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myelodysplastic syndromes and iron metabolism].
    Kawabata H
    Rinsho Ketsueki; 2018; 59(10):2042-2049. PubMed ID: 30305507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.
    Pirotte M; Fillet M; Seidel L; Jaspers A; Baron F; Beguin Y
    Am J Hematol; 2021 Oct; 96(10):1275-1286. PubMed ID: 34310730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
    Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
    Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes.
    Lieu YK; Liu Z; Ali AM; Wei X; Penson A; Zhang J; An X; Rabadan R; Raza A; Manley JL; Mukherjee S
    Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34930825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of erythroferrone structural domains relevant to its iron-regulatory function.
    Srole DN; Jung G; Waring AJ; Nemeth E; Ganz T
    J Biol Chem; 2023 Dec; 299(12):105374. PubMed ID: 37866631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
    Malcovati L; Cazzola M
    Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS.
    Huang Y; Hale J; Wang Y; Li W; Zhang S; Zhang J; Zhao H; Guo X; Liu J; Yan H; Yazdanbakhsh K; Huang G; Hillyer CD; Mohandas N; Chen L; Sun L; An X
    J Hematol Oncol; 2018 Feb; 11(1):19. PubMed ID: 29433555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts.
    Mupo A; Seiler M; Sathiaseelan V; Pance A; Yang Y; Agrawal AA; Iorio F; Bautista R; Pacharne S; Tzelepis K; Manes N; Wright P; Papaemmanuil E; Kent DG; Campbell PC; Buonamici S; Bolli N; Vassiliou GS
    Leukemia; 2017 Mar; 31(3):720-727. PubMed ID: 27604819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.